home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Advances In Uterine Leiomyoma Research: 2nd NIH International Congress

 
  February, 22 2005 8:28
your information resource in human molecular genetics
 
     
U.S. Department of Health and Human Services

NATIONAL INSTITUTES OF HEALTH

NIH News

NIH Office of the Director (OD)
http://www.nih.gov/icd/od/

NIH Office of Research on Women's Health (ORWH)
http://www4.od.nih.gov/orwh/

MEDIA CONTACT:
Vicki Malick
301-402-1770

ADVANCES IN UTERINE LEIOMYOMA RESEARCH: 2ND NIH INTERNATIONAL CONGRESS

WHAT: The National Institutes of Health will host "Advances in Uterine Leiomyoma Research: 2nd NIH International Congress" on February 24-25. This conference will bring together researchers working in the fields of biomedicine, epidemiology, basic research, therapeutics, and translational medicine to foster an exchange of scientific information among members of the uterine leiomyoma (fibroids) research and health care communities.

Fibroids are the most common gynecologic neoplasm in women of reproductive age and the leading cause of hysterectomy in the United States. Topics to be covered include Clinical Experiences and Therapeutic Strategies, Epidemiology, Clinical Trials, Pathogenesis of Smooth Muscle Tumors, and Molecular and Genetics Characteristics.

WHEN: February 24-25, 2005

WHERE: Natcher Conference Center, National Institutes of Health
Bethesda, MD 20892

WHO: This conference will be co-chaired by Dr. Vivian Pinn, Associate
Director for Women's Health and Director, Office of Research on Women's Health (ORWH), NIH and Dr. Kenneth Olden, Director, National Institute of Environmental Health Sciences, NIH. Program co-chairs include Dr. J. Carl Barrett, National Cancer Institute (NCI), Drs. Estella Parrott and James Segars, National Institute of Child Health and Human Development (NICHD), and Dr. Barbara J. Davis, AstraZeneca. Participants will represent academia, medical centers, government, industry, and advocacy groups.

This congress is a joint effort within the Department of Health and Human Services, including the NIH ORWH, NIEHS, NICHD, NCI, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Center for Research Resources (NCRR), and the following DHHS entities: Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health Research and Services Administration (HRSA), Office of Women's Health, Office of the Secretary (OWH), and the Substance Abuse and Mental Health Services Administration (SAMSHA).

For more information or to register, please visit
http://www4.od.nih.gov/orwh/ or call (301) 402-1770.

(C) NIH Office of Research on Women's Health (ORWH) press release.



Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.